A pharmacological profile of clobazam (Mystan®), a new antiepileptic drug

Folia Pharmacologica Japonica

Volumn 118, Issue 2, 2001, Pages 117-122

  Nakajima, H ^a  

^a R and D Division   (Japan)

Author keywords

1,5 benzodiazepine; Clobazam; Epilepsy

Indexed keywords

CLOBAZAM; MYSTAN;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EPILEPSY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; HUMANS; RATS; RECEPTORS, GABA; RECEPTORS, GABA-A; SEIZURES;

EID: 0034896836     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.118.117     Document Type: Review

References (16)

1. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8- chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent
2. Antiepileptic properties of clobazam, a 1,5benzodiazepine in man
3. A receptor channels by diazepam and phenobarbital
4. Anticonvulsant drugs, ion channels and neurotransmitter receptors
5. 3H] zolpidem
6. Anticonvulsant action of clobazam and desmethylclobazam in reflex epilepsy in rodents and baboons
7. Antileptazol activity and kinetics of clobazam and N-desmethyl-clobazam in the guineapig